Abstract #0197

Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy

Francesca Branzoli^1,2, Clément Pontoizeau³, Anna Luisa Di Stefano^4,5, Dinesh K Deelchand⁶, Romain Valabregue^1,2, Stéphane Lehéricy^1,2, Marc Sanson^2,4,7, Chris Ottolenghi³, and Małgorzata Marjańska⁶

¹Centre de NeuroImagerie de Recherche (CENIR), Institut du Cerveau et de la Moelle épinère (ICM), Paris, France, ²Sorbonne Université, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France, ³Centre de Référence des Maladies Métaboliques, Service de Biochimie Métabolique, Hôpital Necker and Université Paris Descartes, Paris, France, ⁴AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neurologie 2, Paris, France, ⁵Department of Neurology, Foch Hospital, Suresnes, Paris, France, ⁶Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN, United States, ⁷Onconeurotek tumor bank, Institut du Cerveau et de la Moelle épinère (ICM), Paris, France

Molecular markers such as mutation in isocitrate dehydrogenase (IDH) and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have highly benefited diagnosis and prognosis in brain gliomas. However, the biological effects of 1p/19q codeletion are still not clear. We report selective accumulation of cystathionine in IDH-mutated, 1p/19q codeleted gliomas observed by edited ¹H magnetic resonance spectroscopy. Noninvasive detection of cystathione enables identification of glioma subtypes in vivo and opens up the possibility of investigating nonivasively cancer-specific metabolic pathways.

This abstract and the presentation materials are available to members only; a login is required.

Join Here